Index RUT
P/E -
EPS (ttm) -5.23
Insider Own 5.95%
Shs Outstand 103.54M
Perf Week 11.76%
Market Cap 1.11B
Forward P/E -
EPS next Y -3.85
Insider Trans -1.26%
Shs Float 97.42M
Perf Month 39.66%
Enterprise Value 727.99M
PEG -
EPS next Q -1.03
Inst Own 92.31%
Short Float 30.48%
Perf Quarter 47.12%
Income -525.91M
P/S 24.41
EPS this Y 20.55%
Inst Trans 2.32%
Short Ratio 6.61
Perf Half Y -5.87%
Sales 45.57M
P/B 1.43
EPS next Y 7.74%
ROA -46.84%
Short Interest 29.69M
Perf YTD -7.89%
Book/sh 7.53
P/C 2.21
EPS next 5Y 31.48%
ROE -57.92%
52W High 28.18 -61.89%
Perf Year -52.20%
Cash/sh 4.86
P/FCF -
EPS past 3/5Y -11.59% -20.04%
ROIC -61.12%
52W Low 5.90 82.03%
Perf 3Y -79.36%
Dividend Est. -
EV/EBITDA -
Sales past 3/5Y 20.53% 6.07%
Gross Margin 77.46%
Volatility 7.87% 7.42%
Perf 5Y -47.64%
Dividend TTM -
EV/Sales 15.98
EPS Y/Y TTM 2.57%
Oper. Margin -1173.09%
ATR (14) 0.72
Perf 10Y -
Dividend Ex-Date -
Quick Ratio 4.90
Sales Y/Y TTM -13.37%
Profit Margin -1154.10%
RSI (14) 69.71
Recom 1.62
Dividend Gr. 3/5Y - -
Current Ratio 4.90
EPS Q/Q 1.81%
SMA20 17.34%
Beta 2.29
Target Price 36.84
Payout -
Debt/Eq 0.15
Sales Q/Q -42.54%
SMA50 23.81%
Rel Volume 0.63
Prev Close 10.73
Employees 403
LT Debt/Eq 0.10
Earnings May 08 BMO
SMA200 -9.84%
Avg Volume 4.49M
Price 10.74
IPO May 06, 2016
Option/Short Yes / Yes
EPS/Sales Surpr. 14.00% 30.18%
Trades
Volume 2,811,317
Change 0.09%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-21-25 Upgrade
Wolfe Research
Peer Perform → Outperform
$21
Mar-05-25 Initiated
H.C. Wainwright
Buy
$30
Feb-28-25 Downgrade
JP Morgan
Overweight → Neutral
$45 → $13
Feb-28-25 Downgrade
Goldman
Neutral → Sell
$9
Jan-27-25 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$56 → $11
Feb-23-24 Downgrade
Goldman
Buy → Neutral
$136 → $32
Feb-15-24 Initiated
Wolfe Research
Peer Perform
Apr-13-23 Initiated
Canaccord Genuity
Buy
$66
Mar-21-23 Initiated
Bernstein
Outperform
$54
Mar-14-23 Upgrade
BMO Capital Markets
Market Perform → Outperform
$54 → $57
Feb-01-23 Initiated
Cantor Fitzgerald
Overweight
$67
Jan-24-23 Upgrade
Citigroup
Sell → Neutral
$48 → $39
Jan-19-23 Downgrade
JMP Securities
Mkt Outperform → Mkt Perform
Oct-11-22 Initiated
Morgan Stanley
Overweight
$84
Sep-21-22 Initiated
JP Morgan
Overweight
$85
Sep-01-22 Initiated
Citigroup
Sell
$50
Jun-17-22 Initiated
BMO Capital Markets
Market Perform
$54
Jun-16-22 Initiated
BofA Securities
Buy
$70
Apr-28-22 Initiated
Credit Suisse
Outperform
$100
Feb-18-22 Initiated
William Blair
Outperform
$144
Show Previous Ratings
Jul-03-25 09:18AM
Jun-27-25 08:03AM
Jun-25-25 10:03AM
Jun-23-25 01:41AM
Jun-18-25 09:35AM
04:06PM
Loading…
Jun-17-25 04:06PM
(Investor's Business Daily) +6.92%
01:32PM
05:44AM
Jun-15-25 10:45AM
Jun-11-25 10:33AM
Jun-05-25 04:01PM
Jun-04-25 10:58AM
09:55AM
08:55AM
May-30-25 10:20AM
05:56AM
Loading…
05:56AM
May-29-25 08:30PM
(Morningstar Research) -22.88%
08:18AM
07:16AM
May-23-25 07:45AM
May-21-25 09:05AM
May-19-25 09:32AM
May-18-25 07:25AM
May-16-25 10:51AM
May-15-25 09:55AM
May-09-25 12:25PM
09:08AM
03:12AM
May-08-25 05:27PM
(Morningstar Research) +13.58%
12:13PM
12:07PM
Loading…
12:07PM
08:45AM
07:30AM
May-07-25 01:25PM
12:09PM
11:57AM
11:55AM
08:59AM
08:15AM
May-06-25 04:01PM
08:40AM
May-05-25 10:00AM
04:44AM
May-01-25 10:01AM
09:30AM
07:30AM
Apr-30-25 10:15AM
Apr-29-25 09:55AM
Apr-23-25 09:50AM
Apr-22-25 05:30AM
(The Wall Street Journal)
Apr-21-25 04:09PM
(Investor's Business Daily) +9.54%
Apr-11-25 05:45AM
Apr-09-25 09:42AM
Apr-04-25 01:42PM
07:28AM
Apr-03-25 04:01PM
12:40PM
(Pharmaceutical Technology)
07:30AM
Apr-01-25 12:41PM
11:50AM
Mar-31-25 10:10AM
Mar-28-25 09:39AM
06:24AM
Mar-27-25 11:36AM
Mar-26-25 07:30AM
Mar-21-25 11:25AM
Mar-19-25 10:27AM
Mar-05-25 09:34AM
Mar-04-25 04:01PM
Feb-28-25 06:01AM
(Morningstar Research) -7.09%
02:10AM
01:17AM
(Thomson Reuters StreetEvents)
Feb-27-25 08:45AM
07:30AM
Feb-26-25 08:56PM
Feb-25-25 05:45AM
Feb-24-25 10:00AM
Feb-20-25 10:00AM
09:57AM
07:30AM
Feb-18-25 05:45AM
Feb-14-25 02:08PM
09:55AM
Feb-06-25 08:10PM
Feb-04-25 04:01PM
Jan-23-25 09:14AM
Jan-22-25 07:30AM
05:00AM
Jan-13-25 03:00AM
(Pharmaceutical Technology)
Jan-11-25 10:20AM
07:36AM
Jan-10-25 01:30PM
03:58AM
Jan-09-25 04:00PM
Jan-06-25 07:30AM
Dec-30-24 03:51PM
Dec-29-24 06:41AM
Dec-11-24 11:57AM
Dec-03-24 04:01PM
Nov-25-24 04:16PM
(Investor's Business Daily)
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Clark Eliana EVP, Chief Technical Officer Jul 01 '25 Sale 9.82 1,022 10,036 95,369 Jul 03 04:11 PM Dube Michael P VP, Chief Accounting Officer Jul 02 '25 Sale 9.95 2,503 24,905 57,137 Jul 03 04:07 PM GOODMAN JESSE Director Jun 30 '25 Sale 9.56 1,547 14,789 25,906 Jul 02 05:50 PM GOODMAN JESSE Director Jul 01 '25 Sale 9.23 1,547 14,279 24,359 Jul 02 05:50 PM Bhanji Muna Director Apr 29 '25 Sale 8.50 265 2,252 19,203 May 01 04:24 PM Clark Eliana EVP, Chief Technical Officer Mar 04 '25 Sale 8.99 679 6,104 95,369 Mar 04 04:43 PM BASTA JAMES EVP, General Counsel Mar 04 '25 Sale 8.99 2,572 23,122 111,925 Mar 04 04:21 PM Bhanji Muna Director Jan 29 '25 Sale 9.97 265 2,642 19,468 Jan 31 04:17 PM Dube Michael P VP, Chief Accounting Officer Jan 03 '25 Sale 12.18 1,372 16,711 45,640 Jan 07 05:23 PM BASTA JAMES EVP, General Counsel Jan 03 '25 Sale 12.18 7,074 86,161 74,497 Jan 07 05:22 PM Lebwohl David EVP, Chief Medical Officer Jan 03 '25 Sale 12.18 9,557 116,404 87,666 Jan 07 05:20 PM Hicks Derek EVP, Chief Business Officer Jan 03 '25 Sale 12.18 6,502 79,194 59,878 Jan 07 05:20 PM LEONARD JOHN M President and CEO Jan 03 '25 Sale 12.18 26,807 326,509 941,115 Jan 07 05:19 PM Sepp-Lorenzino Laura EVP, Chief Scientific Officer Jan 03 '25 Sale 12.18 8,966 109,206 77,388 Jan 07 05:16 PM Clark Eliana EVP, Chief Technical Officer Jan 03 '25 Sale 12.18 7,422 90,400 64,048 Jan 06 04:16 PM Clark Eliana EVP, Chief Technical Officer Jan 02 '25 Sale 12.03 556 6,689 71,470 Jan 06 04:16 PM Dube Michael P VP, Chief Accounting Officer Oct 02 '24 Sale 19.01 2,012 38,248 47,012 Oct 04 05:29 PM